ZYVOX May Lead to Shorter Hospital Stays

TORONTO - Data recently presented during the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto, Canada show that ZYVOX (linezolid injection, tablets and for oral suspension) may help some patients with certain difficult-to-treat infections be discharged from hospitals sooner. ZYVOX, according to its manufacturer Pharmacia, is associated with a significantly higher rate of hospital discharge in the first week of therapy among patients with complicated skin and soft tissue infections. For more information visit www.pharmacia.com.